Aventa Lymphoma based on Hi-C FFPE Sequencing is an Alternative to FISH and Detects Additional Variants Informing Diagnosis and Therapy in Lymphomas

Reference:

Hastie, et al.

16th Annual Meeting of the Cancer Genomics Consortium - Houston, TX

View Poster

Abstract:

Genetic diagnosis in lymphoma relies on histologic examination, immuno-profiling, and often fluorescence in situ hybridization (FISH). Because FISH is performed in a panel of single- or dual-target test formats and analyzed through microscopy and manual image analysis, assessment of multiple target biomarkers can be cumbersome and expensive. As additional biomarkers for diagnosis, subtyping, prognosis, and therapeutic decision making become available, target panels will become larger, posing additional challenges to laboratories. In this study, Hi-C sequencing of FFPE samples was performed to find all genomic rearrangements, genome-wide, and this was compared to clinical FISH for the detection of clinically important variants. ​

Previous
Previous

Arima Genomics Introduces Aventa Lymphoma Test to Resolve Diagnostic Uncertainty in B- and T-Cell Lymphomas

Next
Next

Aventa FusionPlus based on Hi-C FFPE Sequencing Detects Fusions Genome-Wide with High Sensitivity in Solid Tumors